Comparing the current results to its competitors, Actinium Pharmaceuticals Inc reported Revenue increase in the 2 quarter 2026 by 0 % year on year. The revenue growth was below Actinium Pharmaceuticals Inc's competitors' average revenue growth of 13.46 %, achieved in the same quarter.
Actinium Pharmaceuticals Inc's Comment on Competition and Industry Peers
The company operates in the clinical-stage radiopharmaceutical sector alongside competitors such as Telix Pharmaceuticals, Perspective Therapeutics, Clarity Pharmaceuticals, Cellectar Biosciences, Bicycle Therapeutics, Molecular Partners, Ratio Therapeutics, Convergent Therapeutics, Aktis Oncology, Radiopharm Theranostics, and Plus Therapeutics. These companies do not currently compete directly with the company’s product candidates based on biological targets. The company may also face competition from antibody-drug conjugate (ADC) companies targeting solid tumors.
In therapeutic areas relevant to the company’s pipeline, several large pharmaceutical firms have marketed drugs. In prostate cancer, competitors include Johnson & Johnson, Astellas/Pfizer, Bayer, Novartis, and AstraZeneca/Merck. For EGFR mutant non-small cell lung cancer (NSCLC), competitors include AstraZeneca, Johnson & Johnson, Roche, and Daiichi Sankyo. In breast cancer, competitors include Roche, Pfizer, Lilly, Novartis, and AstraZeneca/Daiichi Sankyo. Additionally, AbbVie and Bristol Myers Squibb have therapeutics available in related areas.
Competitors identified in company filings include AbbVie, Aktis Oncology, Astellas/Pfizer, AstraZeneca, AstraZeneca/Merck, Bayer, Bicycle Therapeutics, Bristol Myers Squibb, Cellectar Biosciences, Clarity Pharmaceuticals, Convergent Therapeutics, Daiichi Sankyo, Johnson & Johnson, Lilly, Molecular Partners, Novartis, Perspective Therapeutics, Pfizer, Plus Therapeutics, Radiopharm Theranostics, Ratio Therapeutics, Roche, and Telix Pharmaceuticals.
Ligand Pharmaceuticals Inc operates on a business model focused on discovering and acquiring new drugs and technologies to license them to pharmaceutical companies. They generate revenue through licensing fees, milestone payments, and royalties from the sales of their partnered products. Their approach allows them to leverage their expertise and resources while minimizing risk, ultimately leading to long-term value creation for their shareholders.
Durect Corp operates as a specialty pharmaceutical company that develops and commercializes innovative products for the treatment of chronic diseases. Their business model revolves around the research, development, and commercialization of their proprietary drug delivery technologies and therapeutics to address unmet medical needs.
Adagene Inc is a biotechnology company that develops novel antibody therapeutics for cancer treatment by leveraging its proprietary Dynamic Precision Library platform. Their business model involves partnering with pharmaceutical companies for the development and commercialization of their products.
Adc Therapeutics Sa is a biotechnology company that focuses on the development and commercialization of antibody drug conjugates (ADCs) for the treatment of cancer. Their business model revolves around using their proprietary pyrrolobenzodiazepine (PBD) technology to create highly potent ADCs that selectively target cancer cells while minimizing damage to healthy cells. They aim to collaborate with global pharmaceutical companies to co-develop and potentially commercialize their ADC candidates, generating revenue through licensing agreements and milestone payments.
Sources:
Actinium Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Actinium Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
